Abstract
Tumors convert conventional CD4+ T cells into induced CD4+CD25+FoxP3+ T regulatory (iTreg) cells that serve as an effective means of immune evasion. Therefore, the blockade of conventional CD4+ T cell conversion into iTreg cells represents an attractive target for improving the efficacy of various immunotherapeutic approaches. Using a novel form of 4-1BBL molecule, SA-4-1BBL, we previously demonstrated that costimulation via 4-1BB receptor renders both CD4+and CD8+ T effector (Teff) cells refractory to inhibition by Treg cells and increased intratumoral Teff/Treg cell ratio that correlated with therapeutic efficacy in various preclinical tumor models. Building on these studies, we herein show for the first time, to our knowledge, that signaling through 4-1BB inhibits antigen- and TGF-β-driven conversion of naïve CD4+FoxP3− T cells into iTreg cells via stimulation of IFN-γ production by CD4+FoxP3− T cells. Importantly, treatment with SA-4-1BBL blocked the conversion of CD4+FoxP3− T cells into Treg cells by EG.7 tumors. Taken together with our previous studies, these results show that 4-1BB signaling negatively modulate Treg cells by two distinct mechanisms: i) inhibiting the conversion of CD4+FoxP3− T cells into iTreg cells and ii) endowing Teff cells refractory to inhibition by Treg cells. Given the dominant role of Treg cells in tumor immune evasion mechanisms, 4-1BB signaling represents an attractive target for favorably tipping the Teff:Treg balance toward Teff cells with important implications for cancer immunotherapy.
Highlights
CD4+CD25+FoxP3+ Treg cells play a critical role in peripheral tolerance to self-antigens
Conventional CD4+ T cells were shown to convert into iTreg cells under low dose of antigenic stimulation [15]
To test the effect of SA-4-1BBL on antigen driven conversion, naıve CD4+CD252 OT-II T cells were cocultured with T cell-depleted APCs and varying doses of OT-II epitope OVA323–339 peptide in the presence or absence of SA-41BBL with no exogenous TGF-b
Summary
CD4+CD25+FoxP3+ Treg cells play a critical role in peripheral tolerance to self-antigens. A series of studies in preclinical as well as clinical settings have demonstrated the dominant role of Treg cells in cancer immune evasion mechanisms [1]. Treg cells suppress anti-tumor immune responses by targeting cells of innate, adaptive, and humoral immunity, thereby promoting tumor progression [1,2]. Treg cells present an important therapeutic target for cancer immunotherapy. Consistent with this notion are studies demonstrating that physical depletion of Treg cells using antibodies to various cell surface markers or immunotoxins potentiates immunity to cancer with therapeutic consequences in various preclinical settings [1,5,6]
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have